International Stem Cell Corporation (OTCQB: ISCO) is a
company focused on the therapeutic applications of human parthenogenetic stem
cells (hpSCs) and the development of cell-based research and cosmetic products
leading to commercialization. ISCO’s core technology, parthenogenesis, is
achieved through the creation of pluripotent human stem cells from unfertilized
oocytes (eggs). hpSCs avoid the ethical issues associated with the use or
destruction of viable human embryos. Company scientists have created the first
parthenogenetic, homozygous stem cell line that can be a source of therapeutic
cells for hundreds of millions of individuals of both genders and all ages and
racial background with minimal risk of immune rejection after transplantation.
hpSCs deliver the potential to create the first true stem cell bank,
UniStemCell™.
The company’s resolve to be a leader in the field of
restorative medicine is seen in its partnership with The Florey Institute of
Neuroscience and Mental Health, a globally-recognized brain research center.
The agreement drives both parties to launch phase I/IIa clinical trials on the
effects of human parthenogenetic stem cells in individuals living with
Parkinson’s disease (PD).
The Florey Institute’s credibility is undeniable. The
institute employs a staff of over 500, with its scientists comprising the
largest neuroscience research team in Australia. Work is conducted on a range
of serious diseases, including epilepsy, stroke, PD, Alzheimer’s, traumatic
brain and spinal cord injury, multiple sclerosis, depression, Huntington’s
disease, motor neuron disease, schizophrenia, mental illness and a variety of
addictions.
ISCO’s human cell culture products are made up of adult stem
cells and reagents for regenerative medicine integral in the study of human
renal and bladder diseases and prostate disease, as well as human corneal cells
present in corneal disease and other cell culture reagents and supplements for
the growth and freezing of human cells. International Stem Cell Corp. promotes
and sells skincare products through its website and distribution channels and
human cell culture products through its sales force, OEM partners, and brand
distributors. The company is headquartered in Carlsbad, California, and was
founded in 2001.
For more information, visit www.internationalstemcell.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
